Latest News Archive
Please select Category, Year, and then Month to display items
23 November 2022
|
Story André Damons
Prof Motlalepula Matsabisa, Professor and Director of Pharmacology, will play host to the various stakeholders to network and share knowledge on current developments in indigenous knowledge research and product development, biodiversity, innovation, and commercialisation of the IK-based research products. The Indigenous Knowledge System (IKS) for Health unit in the Department of Pharmacology within the UFS Faculty of Health Sciences was last year awarded an annual Technology Innovation Agency Platform (TIA) grant of R17 million for the next five years.
The research and teaching programme in the School of Clinical Medicine has since been rebranded and is now known as the African Medicines Innovation and Technology Development Platform (AMITD), which will strive to respond to community health needs and address industry research needs and challenges.
The indaba will showcase progress made by TIA and other entities in enriching the development and commercialisation of IK-based innovations. It will take place from 24 to 25 November 2022 in the Equitas Senate Hall at the UFS.
Prof Matsabisa is the chairperson of the World Health Organisation’s (WHO) Regional Expert Advisory Committee on Traditional Medicines for COVID-19. He is also a visiting professor at the Beijing University of Chinese Medicine (BUCM) in Beijing, China, and the Deputy President of the South African Society for Basic and Clinical Pharmacology.

Valuable advice for businesses in difficult times
2013-04-15
 |
Prof Helena van Zyl, Director of the Business School, and Dr Reuel Khoza. Photo: Stephen Collett 15 April 2013 |
Dr Reuel Khoza, Chairman of the Nedbank Group, shared the group’s valuable rules for managing a bank in difficult times in an MBA lecture on the Bloemfontein Campus. Dr Khoza is a visiting professor at the UFS Business School.
He focused in the lecture on the group’s business and leadership model and highlighted some do’s and don’ts:
- Do not surprise your stakeholders on the downside – communicate transparently, particularly when there is bad news.
- Retrenching staff to contain costs should be a last resort – the damage to corporate culture from retrenchments is immense. Follow and support your customers – get as close to them as possible because business changes slowly, but customer behaviour can change in an instant.
- Integrated central capital and funding management.
- Entrench well-established reporting, KPIs and measurement systems.
- Ensure strong independent risk management.
- Manage your cost base – anticipate downturns and re-base your costs to avoid crisis-cost management.
- Take advantage of opportunities – an economic downturn creates a situation where valuations fall and assets are sold off, which can be a great opportunity for acquisitions.
- Keep innovating – innovation does not have to be a costly exercise, as the right culture can promote and encourage experimentation and collaboration.
- Whatever you do – avoid a price war, as expedient pricing decisions may hurt the business in the longer term.